New stock news | ZhiXiang Biotechnology submits application to Hong Kong Stock Exchange
According to the disclosure by the Hong Kong Stock Exchange on June 1st, ZhiXiang Biological (Suzhou) Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Dongxing Securities (Hong Kong) as its exclusive sponsor.
According to the disclosure of the Hong Kong Stock Exchange on June 1st, Zhixiang Life Sciences (Suzhou) Co., Ltd. (referred to as Zhixiang Life Sciences) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Dongxing (Hong Kong) as its exclusive sponsor. The prospectus shows that Zhixiang Life Sciences is a production-driven full-lifecycle CDMO dedicated to biologics. According to Frost & Sullivan data, by the number of commercialized products in 2025, Zhixiang Life Sciences ranks second among CDMO companies in China for biologics, and by revenue in 2025, it ranks third in the field of therapeutic antibody biologics CDMO in China.
Related Articles
Quantum frenzy is rising again! Market subscription demand explodes, ion trap quantum computing leader Quantinuum (QNT.US) raises IPO target.
SYNERTONE (01613): Mo Yina resigns as a non-executive director
US Stock Market Move | Jointly with NVIDIA Corporation entering the consumer PC market, Arm Holdings (ARM.US) opens with a surge of over 15%.
Quantum frenzy is rising again! Market subscription demand explodes, ion trap quantum computing leader Quantinuum (QNT.US) raises IPO target.
SYNERTONE (01613): Mo Yina resigns as a non-executive director
US Stock Market Move | Jointly with NVIDIA Corporation entering the consumer PC market, Arm Holdings (ARM.US) opens with a surge of over 15%.
